Enliven Therapeutics(ELVN) - 2025 Q3 - Quarterly Results

Exhibit 99.1 Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update Completed enrollment of the randomized Phase 1b cohorts of the ongoing ENABLE trial of ELVN-001 in CML Remains on track to initiate Phase 3 pivotal trial of ELVN-001 in 2026 Strong balance sheet with $478 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into the first half of 2029 BOULDER, Colo., Nov. 12, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. ...